By: Rahul Koul
Last updated : April 09, 2026 7:52 pm
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
A sharp cluster of recent USFDA final approvals for generic dapagliflozin tablets—the generic version of AstraZeneca’s blockbuster Farxiga—has put Indian pharma companies back in the spotlight in the US market.
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga.
What makes this especially significant is that the US FDA has only just approved the first generics of dapagliflozin on April 7, 2026, opening a very large and strategically attractive market. The reference brand Farxiga has become one of the most important cardiometabolic medicines globally, used not just in type 2 diabetes, but also increasingly in heart failure and chronic kidney disease, dramatically expanding the addressable patient base.
The commercial opportunity is substantial. Alembic, one of the earliest filers, has indicated an estimated US market size of $10.49 billion for the 12 months ended December 2025, based on IQVIA data. That means even a modest market share can translate into meaningful revenue for Indian generic exporters, particularly those with strong US distribution and payer access.
The bigger story, however, is what this signals strategically for Indian pharma.
First, dapagliflozin belongs to the SGLT2 inhibitor class, one of the fastest-growing therapy areas in chronic disease management. Unlike commoditized oral solids where pricing collapses quickly, this category still offers a better margin profile, at least in the early launch window, because of physician familiarity, expanding guideline use, and relatively fewer immediate competitors.
Second, first-wave entrants stand to benefit from limited competition and potentially shared exclusivity economics. Alembic, for example, has disclosed 180 days of shared generic exclusivity as one of the first ANDA applicants with a Paragraph IV filing. This can support stronger pricing in the initial months before broader competition intensifies.
Third, the approvals validate India’s growing strength in complex chronic therapy generics, moving beyond anti-infectives and plain vanilla oral solids into high-value diabetes-cardio-renal portfolios. This is particularly relevant as US buyers increasingly seek diversified suppliers amid ongoing supply-chain rebalancing and China+1 procurement thinking.
For companies like Lupin and Aurobindo Pharma, which already have strong US generics franchises, dapagliflozin can become a portfolio adjacency play, allowing bundling with diabetes combinations, cardiology brands, and nephrology offerings. Aurobindo’s simultaneous nod for the dapagliflozin + metformin ER combination underlines that this may be only the beginning of a broader SGLT2 franchise build-out.
That said, the window for outsized gains may be short. As more Indian and global generic players enter, price erosion could accelerate sharply, following the typical US oral solid pattern. The winners will likely be companies that combine speed-to-market, manufacturing reliability, litigation preparedness, and channel depth.